General Information
Lilly GZGP
Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared with Placebo in Adult Participants with Obesity or Overweight
| Protocol | J2A-MC-GZGP |
|---|---|
| Identifier | 4900798284 |
| UID | 9816937f-be4a-449a-bd94-0c9e86fa80e6 |
| Status | Follow-up |
| Phase | 3 |
| Category | Obesity / Adult |
| Launch Year | 0 |
| NCT Number | - |
| Created | 2023-03-17 16:12 |
| Last Updated | 2023-11-15 16:08 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2023-11-13 | No |
| Enrollment Open | 2023-07-31 | No |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2023-07-24 | No |
| PI Meeting Start | No | |
| PI Meeting End | No | |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | No | |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Mohseni, Rizwana | RMohseni | No |
| Recruiter | Gomez, Kathie | KGomez | No |
| Coordinator | Andujo, Darlene | DCano | No |
| Regulatory | Romero, Araselly | ARomero | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Eli Lilly and Company |
|---|---|
| Division | Lilly |
| Team | Lilly |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | IQVIA RDS Inc. |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | PaleGoldenrod |
| Currency | - |
